All News
EULAR 2021 Best Abstracts - Day 1
RheumNow faculty reporters scoured the Posters and Presentations from virtual EULAR 2021. Several of these are novel enough to be worthy of your consideration. Below is the list of the six most often retweeted abstracts from Day 1.
Read ArticleLessons learned in SLE
An analysis of SLE samples from SLE 1760 patients with active disease from RCTs illustrated several known and some new targets for SLE treatment (POS0351).
Read ArticleCombination vs. Sequential Therapy for the Treatment of Lupus Nephritis
Combination disease modifying antirheumatic drug (DMARD) therapy may not be only for rheumatoid arthritis; combining disease modifying agents may be the path to better renal response.
Read ArticlePromising options to treat mucocutaneous disease in SLE
Cutaneous lupus erythematosus (CLE) consists of a wide range of dermatologic manifestations seen in people with or without systemic lupus erythematosus (SLE). CLE can be categorised into LE-specific lesions, i.e.
Read ArticleCan the Focus Score predict Lymphoma in Sjogren’s syndrome?
Patients with Sjogren’s syndrome are nearly 19 times more likely to develop lymphoma, so identifying factors that impact this risk development is a major goal in caring for this disorder.
Read ArticleEULAR 2021 - Day 3 Report
Here are a few notable presentations from this past Friday, Day 3 of the EULAR 2021 virtual meeting.
Read ArticleNovel TYK2 Inhibitor Efficacious for Treatment of Psoriatic Arthritis
Dr. Philip Mease et al presented results of a phase II trial (OP0227) at EULAR 2021 that shows the efficacy and safety of an oral tyrosine kinase inhibitor (TYKi), deucravacitinib, for treatment of active psoriatic arthritis (PsA).
Read ArticleHow do we personalize psoriatic arthritis treatment?
It seems like every conference we are presented with data on the newest biologic for treatment of psoriatic arthritis, but the question is, do we need it?
Read ArticleLinks:
Links:
Links:
Links:
Links:
Links:
Links:
Links:
Links:
Links:
Links:
Links: